[1]Patent:WO2004/31153,2004,A2,.Locationinpatent:Page20-22;30
[1]JournalofMedicinalChemistry,1998,vol.41,#24,p.4890-4902
[1]JournalofOrganicChemistry,2003,vol.68,#12,p.4984-4987
[1]JournalofOrganicChemistry,2003,vol.68,#12,p.4984-4987
[2]JournalofMedicinalChemistry,1998,vol.41,#24,p.4890-4902
[1]JournalofOrganicChemistry,2003,vol.68,#12,p.4984-4987
[2]JournalofMedicinalChemistry,1998,vol.41,#24,p.4890-4902
Title: Targeting protein prenylation in progeria.
Journal: Science translational medicine 20130206
Title: Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Journal: Current medicinal chemistry 20130101
Title: Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.
Journal: Proceedings of the National Academy of Sciences of the United States of America 20121009
Title: Medicine. Drug trial offers uncertain start in race to save children with progeria.
Journal: Science (New York, N.Y.) 20120928
Title: A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.
Journal: International journal of cancer 20120801
Title: Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
Journal: Gynecologic oncology 20120801
Title: Lonafarnib for cancer and progeria.
Journal: Expert opinion on investigational drugs 20120701
Title: Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.
Journal: Oncotarget 20120301
Title: Targeted agents for the treatment of metastatic melanoma.
Journal: OncoTargets and therapy 20120101
Title: A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Journal: Journal of neuro-oncology 20111201
Title: Hutchinson-Gilford progeria syndrome with G608G LMNA mutation.
Journal: Journal of Korean medical science 20111201
Title: A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.
Journal: Cancer investigation 20111101
Title: Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
Journal: Cancer 20110901
Title: Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Journal: Journal of neuro-oncology 20110801
Title: The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.
Journal: Pediatric research 20110701
Title: Progeria, rapamycin and normal aging: recent breakthrough.
Journal: Aging 20110701
Title: The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Journal: The Journal of investigative dermatology 20110201
Title: Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology 20110201
Title: Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor.
Journal: Cancer chemotherapy and pharmacology 20110101
Title: The role of HDAC6 in cancer.
Journal: Journal of biomedicine & biotechnology 20110101
Title: Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Journal: Current medicinal chemistry 20110101
Title: Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway.
Journal: Journal of experimental & clinical cancer research : CR 20110101
Title: C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo.
Journal: Cell death & disease 20110101
Title: Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.
Journal: Cancer management and research 20110101
Title: Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.
Journal: PloS one 20110101
Title: Hutchinson-Gilford progeria syndrome with severe calcific aortic valve stenosis.
Journal: Annals of pediatric cardiology 20110101
Title: Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
Journal: Cancer letters 20101101
Title: Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Journal: Journal of medicinal chemistry 20101014
Title: Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.
Journal: British journal of cancer 20100511
Title: Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy.
Journal: Journal of molecular graphics & modelling 20100226
Title: Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.
Journal: Journal of oncology 20100101
Title: Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis.
Journal: Molecular cancer 20100101
Title: Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.
Journal: Journal of carcinogenesis 20100101
Title: Dynamics of lamin-A processing following precursor accumulation.
Journal: PloS one 20100101
Title: Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition.
Journal: PloS one 20100101
Title: RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.
Journal: Breast cancer research : BCR 20100101
Title: c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL.
Journal: Molecular cancer 20100101
Title: Virtual screening and pharmacophore studies for ftase inhibitors using Indian plant anticancer compounds database.
Journal: Bioinformation 20100101
Title: Design, Synthesis and Evaluation of Novel 1-(Substituted Acetyl)-4-(10-Bromo-8-Chloro-5,6-Dihydro-11H-Benzo[5,6]Cyclohepta[1,2-B]Pyridine-11-Ylidene)piperidines as Antitumor Agents and Farnesyl Protein Transferase Inhibitors.
Journal: Indian journal of pharmaceutical sciences 20100101
Title: Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
Journal: International journal of cancer 20091201
Title: [Targeting KRAS pathway in NSCLC therapy].
Journal: Bulletin du cancer 20091201
Title: Current data and strategy in glioblastoma multiforme.
Journal: Journal of medicine and life 20091115
Title: Meroterpenes from Dichrostachys cinerea inhibit protein farnesyl transferase activity.
Journal: Journal of natural products 20091001
Title: A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.
Journal: American journal of clinical oncology 20090601
Title: Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Journal: Journal of chemotherapy (Florence, Italy) 20090601
Title: The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.
Journal: The Journal of biological chemistry 20090410
Title: Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors.
Journal: PloS one 20090101
Title: Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity.
Journal: Cancer cell international 20090101
Title: Current available therapies and future directions in the treatment of malignant gliomas.
Journal: Biologics : targets & therapy 20090101
Title: Managing myelodysplastic symptoms in elderly patients.
Journal: Clinical interventions in aging 20090101
Title: Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.
Journal: Annals of hematology 20081101
Title: Mass spectrometric studies of potent inhibitors of farnesyl protein transferase--detection of pentameric noncovalent complexes.
Journal: Journal of mass spectrometry : JMS 20081001
Title: Autophagy induced by farnesyltransferase inhibitors in cancer cells.
Journal: Cancer biology & therapy 20081001
Title: A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology 20080901
Title: On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Journal: Leukemia 20080901
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20080901
Title: Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.
Journal: Biologics : targets & therapy 20080901
Title: Tumorigenic activity and therapeutic inhibition of Rheb GTPase.
Journal: Genes & development 20080815
Title: The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
Journal: Cancer chemotherapy and pharmacology 20080801
Title: [Targeted therapy for locally advanced and/or metastatic bladder cancer].
Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080701
Title: Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Journal: British journal of haematology 20080501
Title: Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Journal: Gynecologic oncology 20080401
Title: Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080301
Title: Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).
Journal: Therapeutics and clinical risk management 20080201
Title: Exploring three-dimensional quantitative structural activity relationship (3D-QSAR) analysis of SCH 66336 (Sarasar) analogues of farnesyltransferase inhibitors.
Journal: European journal of medicinal chemistry 20080101
Title: SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2.
Journal: Anti-cancer drugs 20080101
Title: Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas.
Journal: Molecular cancer 20080101
Title: Molecular targeted therapies for breast cancer treatment.
Journal: Breast cancer research : BCR 20080101
Title: The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.
Journal: Biologics : targets & therapy 20071201
Title: Tipifarnib in the treatment of acute myeloid leukemia.
Journal: Biologics : targets & therapy 20071201
Title: Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.
Journal: International journal of clinical pharmacology and therapeutics 20071001
Title: Farnesyl transferase inhibitor resistance probed by target mutagenesis.
Journal: Blood 20070915
Title: Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.
Journal: Blood 20070915
Title: Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Journal: Cancer 20070915
Title: Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Journal: Anti-cancer drugs 20070901
Title: The molecular genetics of breast cancer and targeted therapy.
Journal: Biologics : targets & therapy 20070901
Title: Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070720
Title: Farnesyltransferase inihibitors in hematologic malignancies.
Journal: Blood reviews 20070701
Title: The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
Journal: The Journal of biological chemistry 20070629
Title: New agents for treatment of advanced transitional cell carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20070501
Title: The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.
Journal: Leukemia 20070401
Title: Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function.
Journal: Molecular cancer therapeutics 20070401
Title: Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
Journal: Leukemia research 20070301
Title: Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070115
Title: Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.
Journal: Breast cancer research : BCR 20070101
Title: A generalized response surface model with varying relative potency for assessing drug interaction.
Journal: Biometrics 20061201
Title: Identification of unstable metabolites of Lonafarnib using liquid chromatography-quadrupole time-of-flight mass spectrometry, stable isotope incorporation and ion source temperature alteration.
Journal: Journal of mass spectrometry : JMS 20061101
Title: Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
Journal: British journal of cancer 20060918
Title: Lonafarnib in cancer therapy.
Journal: Expert opinion on investigational drugs 20060601
Title: Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar).
Journal: Drug metabolism and disposition: the biological fate of chemicals 20060401
Title: [Farnesyl transferase inhibitors--a novel agent for breast cancer].
Journal: Ai zheng = Aizheng = Chinese journal of cancer 20060401
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20060301
Title: Farnesyltransferase inhibitors in myelodysplastic syndrome.
Journal: Current hematologic malignancy reports 20060301
Title: Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Journal: Cancer 20060115
Title: Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20060115
Title: Myelodysplasia: when to treat and how.
Journal: Best practice & research. Clinical haematology 20060101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20060101
Title: The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
Journal: Blood 20051215
Title: Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.
Journal: Chemistry & biology 20051201
Title: Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.
Journal: Journal of the National Cancer Institute 20050907
Title: The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Journal: The Journal of biological chemistry 20050902
Title: Development of farnesyl transferase inhibitors: a review.
Journal: The oncologist 20050901
Title: [Molecular targeted therapy for malignant brain tumors].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20050901
Title: Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
Journal: Molecular pharmacology 20050801
Title: Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Journal: Cancer 20050801
Title: Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
Journal: Leukemia 20050701
Title: Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells.
Journal: Cancer research 20050701
Title: Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
Journal: Journal of medicinal chemistry 20050602
Title: Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.
Journal: International journal of cancer 20050501
Title: Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.
Journal: Current drug targets 20050501
Title: Farnesyltransferase inhibitors in myelodysplastic syndrome.
Journal: Current hematology reports 20050501
Title: The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Journal: Cancer research 20050501
Title: Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.
Journal: European journal of cancer (Oxford, England : 1990) 20050501
Title: Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20050415
Title: Hit to Lead Success Stories--IBC Conference: Effective chemistry strategies for reducing attrition rates and speeding lead compounds into the pipeline. 31 January-1 February 2005, San Diego, CA, USA.
Journal: IDrugs : the investigational drugs journal 20050301
Title: [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
Journal: Bulletin du cancer 20050301
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20050301
Title: The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
Journal: The Biochemical journal 20050215
Title: Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia.
Journal: Leukemia 20050201
Title: A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.
Journal: Urologic oncology 20050101
Title: Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry.
Journal: Rapid communications in mass spectrometry : RCM 20050101
Title: Synthesis of 5-bromopyridyl-2-magnesium chloride and its application in the synthesis of functionalized pyridines.
Journal: Organic letters 20041223
Title: Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding.
Journal: Bioorganic & medicinal chemistry letters 20041206
Title: Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability.
Journal: Bioorganic & medicinal chemistry letters 20041206
Title: Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyltransferase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20041101
Title: The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
Journal: Cancer biology & therapy 20041101
Title: Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Journal: Leukemia & lymphoma 20041101
Title: Farnesyltransferase inhibition: who are the Aktors?
Journal: Cancer biology & therapy 20041101
Title: Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Journal: Journal of the National Cancer Institute 20041020
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20040901
Title: Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator.
Journal: Bioorganic & medicinal chemistry letters 20040802
Title: Farnesyltransferase inhibitors as anticancer agents: critical crossroads.
Journal: Current opinion in drug discovery & development 20040701
Title: Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis.
Journal: The Journal of biological chemistry 20040618
Title: Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20040501
Title: Novel agents and incremental advances in the treatment of head and neck cancer.
Journal: Seminars in oncology 20040401
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20040301
Title: In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
Journal: Oncology reports 20040201
Title: Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.
Journal: Journal of medicinal chemistry 20040129
Title: Cancer treatment with kinase inhibitors: what have we learnt from imatinib?
Journal: British journal of cancer 20040112
Title: A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
Journal: Leukemia 20040101
Title: [Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology 20040101
Title: New targets for therapy in breast cancer: farnesyltransferase inhibitors.
Journal: Breast cancer research : BCR 20040101
Title: [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].
Journal: Wiadomosci lekarskie (Warsaw, Poland : 1960) 20040101
Title: The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2.
Journal: Chemotherapy 20031201
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20031101
Title: Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
Journal: Seminars in oncology 20031001
Title: Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.
Journal: Cancer research 20030815
Title: Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Journal: Clinical lymphoma 20030801
Title: High-performance liquid chromatography-atmospheric pressure photoionization/tandem mass spectrometric analysis for small molecules in plasma.
Journal: Analytical chemistry 20030701
Title: A novel enantioselective alkylation and its application to the synthesis of an anticancer agent.
Journal: The Journal of organic chemistry 20030613
Title: Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Journal: International journal of cancer 20030610
Title: Farnesyl transferase inhibitors in clinical development.
Journal: Expert opinion on investigational drugs 20030601
Title: Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.
Journal: Bioorganic & medicinal chemistry letters 20030407
Title: Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Journal: Current oncology reports 20030301
Title: Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line.
Journal: Blood 20030301
Title: Farnesyl transferase inhibitors in the treatment of breast cancer.
Journal: Expert opinion on investigational drugs 20030301
Title: Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.
Journal: Molecular cancer therapeutics 20030301
Title: Overcoming resistance to imatinib by combining targeted agents.
Journal: Molecular cancer therapeutics 20030301
Title: Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferase.
Journal: Bioorganic & medicinal chemistry 20030102
Title: Targeting RAS signalling pathways in cancer therapy.
Journal: Nature reviews. Cancer 20030101
Title: Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
Journal: Current topics in medicinal chemistry 20030101
Title: Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.
Journal: Anticancer research 20030101
Title: Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.
Journal: European journal of cancer (Oxford, England : 1990) 20021101
Title: Farnesyl transferase inhibitors as anticancer agents.
Journal: European journal of cancer (Oxford, England : 1990) 20020901
Title: Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
Journal: Anti-cancer drugs 20020901
Title: Gateways to Clinical Trials.
Journal: Methods and findings in experimental and clinical pharmacology 20020901
Title: Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.
Journal: Journal of medicinal chemistry 20020829
Title: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.
Journal: Blood 20020801
Title: A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20020701
Title: Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
Journal: Experimental cell research 20020215
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20020101
Title: Agents targeting ras signaling pathway.
Journal: Current pharmaceutical design 20020101
Title: Farnesyltransferase inhibitors in breast cancer therapy.
Journal: Cancer investigation 20020101
Title: An anion-induced regio- and chemoselective acylation and its application to the synthesis of an anticancer agent.
Journal: Organic letters 20011115
Title: Current status of clinical trials of farnesyltransferase inhibitors.
Journal: Current opinion in oncology 20011101
Title: The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
Journal: Cancer research 20011015
Title: Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336.
Journal: Current medicinal chemistry 20011001
Title: Farnesyltransferase inhibitors.
Journal: Seminars in oncology 20011001
Title: Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
Journal: Cancer research 20010601
Title: Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20010501
Title: Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.
Journal: Blood 20010301
Title: Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Journal: Blood 20010301
Title: Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010215
Title: The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
Journal: Experimental cell research 20010101
Title: Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Journal: Cancer research 19981101
Title: Liu M, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 1998 Nov 1;58(21):4947-56.
Title: Chaponis D, et al. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011 Aug;104(1):179-89.
Title: Koh C,et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015 Oct;15(10):1167-1174.
